Amoytop 特宝生物
29 significant filings since 31 May 2026: 20 on share issue, 6 on buyback and 3 on new listing. The latest, on 12 Sep 2026: 特宝生物：关于可转债投资者适当性要求的风险提示性公告.
自 31 May 2026 起有 29 份重大公告：share issue 20 份、buyback 6 份、new listing 3 份。最新一份（12 Sep 2026）：特宝生物：关于可转债投资者适当性要求的风险提示性公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 东海证券 | 杜永宏 | Buy 买入 | 1 Sep 2026 | 3 | — |
| 国金证券 | 甘坛焕,马居东 | Buy 买入 | 19 Aug 2026 | 5 | — |
| 太平洋 | 李忠华,程晓东 | Buy 买入 | 11 Jun 2026 | 1 | — |
| 国信证券 | 马千里,陈曦炳,彭思宇 | Outperform 增持 | 1 Apr 2026 | 2 | — |
| 华安证券 | 谭国超,任婉莹 | Buy 买入 | 27 Oct 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 1 of 12 reports. 每行为该券商近十二个月的最新研报；12 份中 1 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。